Compliance Rate

Compliance Rate 50.0%
Compliant submissions 1
Incompliant submissions 1
Total trials 2

My Organizations' Clinical Trials

Showing 950 of 3499 entries
View as:

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma That Has Not Responded to Previous Treatment

Phase: N/A Priority: Normal
NCT ID: NCT00022438 Org: User:
Start: 06/30/01 End: 08/31/04 Due: 08/31/05

Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT03220009 Org: User:
Start: 11/03/17 End: 07/01/21 Due: 07/01/22

AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT01085214 Org: User:
Start: 03/31/10 End: 03/31/12 Due: 03/31/13

Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT00644228 Org: User:
Start: 07/28/08 End: 09/18/25 Due: 09/18/26

Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00658814 Org: User:
Start: 12/01/08 End: 03/19/26 Due: 03/19/27

Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...

Phase: N/A Priority: Normal
NCT ID: NCT06161532 Org: User:
Start: 08/01/24 End: 11/01/28 Due: 11/01/29

Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT04840589 Org: User:
Start: 02/02/22 End: 01/01/26 Due: 01/01/27

Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT06465316 Org: User:
Start: 12/06/24 End: 09/16/26 Due: 09/16/27

UMCC 2003-064 Resveratrol in Preventing Cancer in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT00098969 Org: User:
Start: 09/30/04 End: - Due: -

Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma

Phase: N/A Priority: Normal
NCT ID: NCT00458731 Org: User:
Start: 05/31/07 End: - Due: -

Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma

Phase: N/A Priority: Normal
NCT ID: NCT06654050 Org: User:
Start: 07/02/25 End: 12/31/27 Due: 12/31/28

[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

Phase: N/A Priority: Normal
NCT ID: NCT06479811 Org: User:
Start: 07/02/25 End: 01/01/32 Due: 01/01/33

Immunotherapies in Combination With Stereotactic Body Radiation Radiotherapy in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC)

Phase: N/A Priority: Normal
NCT ID: NCT06603818 Org: User:
Start: 07/02/25 End: 06/01/27 Due: 06/01/28

Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT03805932 Org: User:
Start: 10/03/19 End: 06/30/25 Due: 06/30/26

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

Phase: N/A Priority: Normal
NCT ID: NCT06770582 Org: User:
Start: 06/03/25 End: 02/01/32 Due: 02/01/33

National Cancer Institute "Cancer Moonshot Biobank"

Phase: N/A Priority: Normal
NCT ID: NCT04314401 Org: User:
Start: 11/11/20 End: 09/16/25 Due: 09/16/26

Collection and Distribution of Samples From Healthy Donors for In Vitro Research at the NCI-Frederick

Phase: N/A Priority: Normal
NCT ID: NCT00339911 Org: User:
Start: 11/01/99 End: 10/13/30 Due: 10/13/31

Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02567422 Org: User:
Start: 04/17/17 End: 05/14/26 Due: 05/14/27

Integrated Genomic Prostate Score With MRI Targeted Prostate Biopsies

Phase: N/A Priority: Normal
NCT ID: NCT04541030 Org: User:
Start: 09/02/20 End: 03/01/26 Due: 03/01/27

Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis

Phase: N/A Priority: Normal
NCT ID: NCT01441089 Org: User:
Start: 05/21/12 End: - Due: -

Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03811015 Org: User:
Start: 08/16/19 End: 01/01/27 Due: 01/01/28

Capravirine to Treat Children With HIV Infection

Phase: N/A Priority: Normal
NCT ID: NCT00006519 Org: User:
Start: 11/30/00 End: 10/31/04 Due: 10/31/05

Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas

Phase: N/A Priority: Normal
NCT ID: NCT03220022 Org: User:
Start: 03/16/18 End: 07/20/25 Due: 07/20/26

Comprehensive Omics Analysis of Pediatric Solid Tumors and Establishment of a Repository for Related Biological Studies

Phase: N/A Priority: Normal
NCT ID: NCT01109394 Org: User:
Start: 04/21/10 End: - Due: -

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

Phase: N/A Priority: Normal
NCT ID: NCT03191149 Org: User:
Start: 04/25/18 End: 06/30/27 Due: 06/30/28